deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT05251259

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma (FLASH)

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults With Moderate to Severe Uncontrolled Asthma

Sponsor: AstraZeneca

Conditions Asthma
Interventions Atuliflapon Placebo
Updated 36 times since 2022 Last updated: Jan 13, 2026 Started: Jan 27, 2022 Primary completion: Jan 7, 2026 Completion: Jan 7, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05251259, this PHASE2 trial focuses on Asthma and remains completed. Sponsored by AstraZeneca, it has been updated 36 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Nov 2022 · 31 days · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Aug 2023 · 4 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – present · 3 months · monthly snapshot

Change History

36 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2026 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

  5. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

▶ Show 31 earlier versions

  1. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE2

  2. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE2

  3. May 2025 — Jun 2025 [monthly]

    Recruiting PHASE2

  4. Apr 2025 — May 2025 [monthly]

    Recruiting PHASE2

  5. Mar 2025 — Apr 2025 [monthly]

    Recruiting PHASE2

  6. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE2

  7. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE2

  8. Dec 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  9. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  10. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  11. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  12. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  13. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  14. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  15. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  16. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE2

  17. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE2

  18. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

  19. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE2

  20. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  21. Sep 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  22. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  23. Apr 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  24. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  25. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  26. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  27. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  28. Oct 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  29. Sep 2022 — Oct 2022 [monthly]

    Recruiting PHASE2

  30. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  31. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Ann Arbor, United States , Austin, United States , Badalona, Spain , Bahía Blanca, Argentina , Bakersfield, United States , Barcelona, Spain , Beaumont, United States , Belgrade, Serbia , Bellaire, United States and 182 more locations